Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Sweden
/
Healthcare
/
OssDsign
OSSD
OssDsign
Rising US Healthcare Cost Controls Will Squeeze Orthobiologics Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
SEK 12.00
18.2% overvalued
intrinsic discount
24 Aug
SEK 14.18
1Y
83.9%
7D
-14.3%
Loading
1Y
83.9%
7D
-14.3%
Author's Valuation
SEK 12.0
18.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
SEK 12.0
18.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-109m
312m
2017
2019
2021
2023
2025
2027
2028
Revenue SEK 312.2m
Earnings SEK 31.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
24.57%
Medical Equipment revenue growth rate
0.45%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.54%
Calculation
SEK 31.82m
Earnings '28
x
43.31x
PE Ratio '28
=
SEK 1.38b
Market Cap '28
SEK 1.38b
Market Cap '28
/
97.66m
No. shares '28
=
SEK 14.11
Share Price '28
SEK 14.11
Share Price '28
Discounted to 2025 @ 5.55% p.a.
=
SEK 12.00
Fair Value '25
